Super Sam Foundation Reaffirms Support for Oncoheroes' Pediatric Cancer Drive

by Oncoheroes Biosciences

9 days ago
volasertib, pediatric cancer, Oncoheroes Biosciences

As Oncoheroes prepares to evaluate the efficacy of its lead compound, volasertib, across five pediatric cancer indications, including rhabdomyosarcoma, the Super Sam Foundation once again steps forwar...

Oncoheroes Announces Advancement in Pediatric Cancer Research

by Oncoheroes Biosciences

14 days ago
medulloblastoma, Oncoheroes

Oncoheroes Biosciences reveals the development of an innovative screening platform aimed at identifying potential drug candidates for medulloblastoma, a type of brain cancer prevalent in children

Oncoheroes Biosciences: the pivotal role of non-profits in pediatric drug development

by Oncoheroes Biosciences

2 months ago
volasertib, Oncoheroes Biosciences

Their primary goal is securing the necessary funding to propel the testing of our lead compound, volasertib, in five types of pediatric cancer (Ewing’s sarcoma, alveolar rhabdomyosarcoma, medullobla...

Oncoheroes & Ally Anderson Alveolar Rhabdomyosarcoma Research Fund Supported by Arms Wide Open Childhood Cancer Foundation Join Forces to Test Volasertib’s Potential

by Oncoheroes Biosciences

3 months ago
pediatric cancers, Volasertib, Rhabdomyosarcoma, Ally Anderson Alveolar Rhabdomyosarcoma Research Fund, Oncoheroes

Oncoheroes Biosciences is now at a crucial moment in its quest to find effective therapies for pediatric cancer patients, as they have the unprecedented opportunity to test Volasertib, one of its thre...

Dovitinib, a potential new treatment for osteosarcoma, receives Orphan Drug Designation from the U.S. FDA

by Oncoheroes Biosciences

6 months ago
dovitinib, osteosarcoma, Orphan Drug Designation (ODD)

Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to dovit...

FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials

by Oncoheroes Biosciences

7 months ago
volasertib, dovitinib, Oncoheroes

Oncoheroes Biosciences, Inc. (“Oncoheroes”) announced today that the U.S. Food and Drug Administration (FDA) has allowed the Boston-based biotech to proceed with the investigation of two potential...

Foundation for Addie’s Research Joins Oncoheroes To Create More and Better Options for Children Fighting Cancer

by Oncoheroes Biosciences

2 years ago
volasertib, Foundation for Addie’s Research, Oncoheroes

Foundation for Addie’s Research Joins Oncoheroes moving volasertib into a clinical trial to create more and better options for children fighting cancer.

Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences to Partner for the Discovery and Development of Novel Therapies for Childhood Sarcomas

by Oncoheroes Biosciences

2 years ago
pediatric sarcomas, rhabdomyosarcoma (RMS), Vall d’Hebron Research Institute (VHIR), Oncoheroes Biosciences

Vall d’Hebron Research Institute (VHIR), a world-leading healthcare institution where healthcare, research, innovation and education go hand in hand, and Oncoheroes Biosciences, a biotech company ex...

Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib

by Oncoheroes Biosciences

2 years ago
Allarity Therapeutics, Oncoheroes Biosciences, FDA, Stenoparib, Dovitinib, children’s cancer

Oncoheroes Biosciences, Inc. (“Oncoheroes”), and Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”) have signed a worldwide, exclusive pediatric licensing agreement for dovitinib, a pan-t...

Oncoheroes Biosciences Receives A Second Investment From Rally Foundation

by Oncoheroes Biosciences

2 years ago
Rally Foundation, Childhood Cancer Research

In April 2021, Rally Foundation For Childhood Cancer Research invested for the first time in Oncoheroes Biosciences. Today, we are thrilled to announce that Rally Foundation is investing again ba...

WEBINAR: Why Childhood Cancer Foundations Are Adopting The Venture Philantropy Approach

by Oncoheroes Biosciences

2 years ago
childhood cancer, Oncoheroes Biosciences

Venture philanthropy is a growing trend across many important social issues.

Oncoheroes Biosciences receives a second investment from The Andrew McDonough B+ Foundation

by Oncoheroes Biosciences

2 years ago
Andrew McDonough B+ Foundation, Oncoheroes Biosciences, childhood cancer

In October 2019, The Andrew McDonough B+ Foundation invested for the first time in Oncoheroes Biosciences, a biotech company advancing new therapies for childhood cancer. The B+ Foundation was the fir...